Previous 10 | Next 10 |
Introduction This forensic value analysis began with a check of four different algorithm scores of Tesla, Inc. ( TSLA ) at the request of members of my service back in October 2018. The question they asked at the time was, "what risk does Tesla, Inc. pose as an investment?" In an ad-hoc quer...
The following slide deck was published by Portola Pharmaceuticals, Inc. in conjunction with this Read more ...
SOUTH SAN FRANCISCO, Calif. , Sept. 19, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. (Nasdaq: PTLA) today announced the appointment of Ted W. Love , M.D., to its Board of Directors. Dr. Love is a recognized industry leader with more than 25 years of experience in the discovery...
Introduction This forensic value analysis began with a check of four different algorithm scores of Tesla Inc. ( TSLA ) at the request of members of my service back in October 2018. The question they asked at the time was, "what risk does Tesla Inc. pose as an investment?" In an ad hoc quer...
SOUTH SAN FRANCISCO, Calif. , Aug. 13, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) today announced the pricing of its underwritten public offering of 8,035,715 shares of its common stock at a price to the public of $28.00 per share. In addition, the underwriter...
Portola Pharmaceuticals (NASDAQ:PTLA) today announced that it would offer $200 million USD of its common stock in an underwritten public offering. PTLA stock fell 1.7% to $30.11 off the back of the announcement. PTLA Stock Offering Portola is a San Francisco-based pharmaceuticals c...
Portola Pharmaceuticals (NASDAQ: PTLA ) is down 4.8% after filing to offer $200M in common shares. More news on: Portola Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
SOUTH SAN FRANCISCO, Calif. , Aug. 12, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced plans to offer, subject to market and other conditions, $200 million of its common stock in an underwritten public offering. The company expects to...
Portola Pharmaceuticals, Inc. (PTLA) Q2 2019 Earnings Conference Call August 07, 2019 4:30 PM ET Company Participants Cara Miller - Vice President of Investor Relations & Corporate Communications Scott Garland - President & Chief Executive Officer Mardi Dier - Chief Finan...
The following slide deck was published by Portola Pharmaceuticals, Inc. in conjunction with their 2019 Q2 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
Portola Pharmaceuticals Inc. Company Name:
PTLA Stock Symbol:
NASDAQ Market:
Portola Pharmaceuticals Inc. Website:
SOUTH SAN FRANCISCO, Calif. , May 18, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) today announced that, due to the public health impact of the coronavirus (COVID-19) pandemic and to prioritize the health and well-being of stockholders, employees and othe...
SOUTH SAN FRANCISCO, Calif. , May 14, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has proposed extending the New Technology Add-on Payment (NTAP) for Andexxa ® [coagula...
SOUTH SAN FRANCISCO, Calif. , May 11, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today reported financial results for the three months ended March 31, 2020, and provided a corporate update, including the Company's actions to continue to su...